Ontology highlight
ABSTRACT:
SUBMITTER: Kim JJ
PROVIDER: S-EPMC4400463 | biostudies-literature | 2012 Feb
REPOSITORIES: biostudies-literature
Clinical kidney journal 20120130 1
Disorders in complement regulation are a major cause of atypical haemolytic-uraemic syndrome (aHUS). Eculizumab, a monoclonal antibody targeting complement C5 and blocking the terminal complement cascade, should theoretically be useful in this disease, particularly when associated with specific complement pathway anomalies such as Factor H deficiency. Eculizumab is emerging as an effective treatment for post-transplant aHUS recurrence and may have a role in treating de novo aHUS, halting the hae ...[more]